ArticlePloS one2014

High-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation.

Shakti A Goel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.